Keros Therapeutics considers sale amid investor pressure
Keros Therapeutics’ board of directors has authorised a ‘poison pill defence’— in response to increasing investor interest in “influencing the…
News
Cingulate secures $3m to advance once-daily anxiety treatment
Tempest hits funding block for Phase III liver cancer drug-in-waiting
MHRA reconfirmed as WHO biologics partner amid US withdrawal
“Resign or be fired” – APHA executive director calls out RFK Jr
PharmaLogic to boost radiopharma offerings with Agilera acquisition
FDA approves injectable antibiotics for B Braun drug delivery system
Merida launches with $121m to target autoimmune antibodies
